Cerebral Palsy Treatment Market Expected to Reach $4,365.01 million by 2030

According to a new report published by Allied Market Research, titled, “Cerebral Palsy Treatment Market by drug type, disease type, distribution channel and region: Global Opportunity Analysis and Industry Forecast, 2021–2030,” The global cerebral palsy treatment market size was valued at $3166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Cerebral palsy is a problem that affects muscle tone, movement, and coordination. It happens when the brain cannot properly send messages to muscles about how to move in smooth or well-coordinated way. It can also affect other body functions that involve motor skills and muscles, such as breathing, bladder and bowel control, eating, and talking.

Rapid growth of the cerebral palsy treatment market is attributed to increase incidences of cerebral palsy, coupled with rise in awareness among parents regarding complications of cerebral palsy and availability of various treatments options. The market for cerebral palsy treatment has witnessed tremendous growth in the recent years, owing to surge in demand for the medication.

Rise in incidences of cerebral palsy can be attributed to multiple factors, such as premature birth or low weight at the time of birth, multiple child births, and incidences of infectious diseases at the time of pregnancy. Further, health conditions of mother may also lead to cerebral palsy in the child through conditions such as thyroid, seizures, and intellectual disability. Rapid growth of the cerebral palsy treatment market can be attributed to increase in incidences of cerebral palsy, coupled with rise in awareness among parents regarding complications of cerebral palsy and availability of various treatments options in the market. However, side effects associated with drugs are expected to limit growth of the cerebral palsy treatment market in the next few years.

Increase in number of approvals and product launches among key players and biopharmaceutical companies and technological advancements in cerebral palsy treatment fuel growth of the market.

The cerebral palsy treatment market is segmented on the basis of drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into anticholinergics, anticonvulsants, antidepressants, and others. The anticonvulsants segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to increasing prevalence rate of cerebral palsy and rise in the approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA).

By disease type, the cerebral palsy treatment market is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. The spastic cerebral palsy segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, as 80% of the total cerebral palsy patients are suffering from spastic cerebral palsy.

Depending on distribution channel, the market is classified into hospital pharmacies, retail stores and pharmacy, and online providers. The retail stores and pharmacy segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to recent upgrades in the pharmaceutical sector, increase in expenses on the health & medicines, easy access to pharmaceuticals for general population, rise in awareness for cerebral palsy disorders, thereby encouraging treatments, which boost health insurance penetration.

North America accounted for a majority of the global cerebral palsy treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to significant rise in investments as well as partnerships and collaborations.

The key players in this market have adopted product launch as one of their key developmental strategies such as acquisitions and partnerships. The major companies profiled in the report include Merz Pharmaceuticals, LLC., Pfizer, Inc., Teva Pharmaceuticals, Bayer AG, Johnson and Johnson, GSK, Novartis, Abbvie, Par Pharmaceuticals and LAnnett Company.

Key Findings Of The Study

• By drug type, the anticonvulsants segment was the highest contributor to the market in 2020 and is expected to continue during the forecast period owing to increasing prevalence rate of cerebral palsy, and rise in the approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA).
• By disease type, the spastic cerebral palsy segment dominated the global cerebral palsy treatment market in 2020, as around 80% of the total cerebral palsy patients are suffering from spastic cerebral palsy.
• Based on distribution channel, the retail stores and pharmacy segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period owing to recent upgrades in the pharmaceutical sector, increase in expenses on the health & medicines, easy access to pharmaceuticals for the general population, rise in awareness for cerebral palsy disorders thereby encouraging the treatments, and boost in the health insurance penetration.
• On the basis of region, in 2020, North America dominated the market in 2020, owing to significant rise in investments as well as partnerships and collaborations.